Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study

• Главные авторы: Giuseppe Armentaro (Автор), Graziella D'Arrigo (Автор), Marcello Magurno (Автор), Alfredo F. Toscani (Автор), Valentino Condoleo (Автор), Sofia Miceli (Автор), Velia Cassano (Автор), Raffaele Maio (Автор), Franco Arturi (Автор), Giovanni Tripepi (Автор), Giorgio Sesti (Автор), Angela Sciacqua (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durab...